Transgene Struggles With NSCLC Vaccine, Even As Positive Data Flow In
This article was originally published in Scrip
Executive Summary
Strasbourg, France-based Transgene has presented final overall survival data from a Phase IIb trial of its non-small cell lung cancer vaccine, TG4010, confirming that the product works – but prospects for the vaccine on a competitive lung cancer market remain questionable.